The Evolution of Lung Cancer Therapies at a Glance
By Ruchi Jhonsa, Ph.D. In 1910, esteemed surgeon Alton Ochsner recalled, “As a student, I was asked to witness an autopsy of a patient with lung cancer because I was …
Read MoreThe Next Generation Biotech Media
By Ruchi Jhonsa, Ph.D. In 1910, esteemed surgeon Alton Ochsner recalled, “As a student, I was asked to witness an autopsy of a patient with lung cancer because I was …
Read MoreBy Rajaneesh K. Gopinath, Ph.D. Following outstanding performance in the ADAURA trial conducted in patients with a type of non-small cell lung cancer (NSCLC), AstraZeneca’s blockbuster drug Tagrisso is recommended …
Read MoreLast week, AstraZeneca announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has granted its PARP inhibitor Lynparza (olaparib), an orphan drug designation for the maintenance treatment of germline …
Read More20191223-1229 USFDA Nods on Daiichi Sankyo and AstraZeneca’s Breast Cancer Drug Human epidermal growth factor receptor 2 (HER2)-positive breast cancer is a difficult-to-treat breast cancer population, in which HER2 promotes …
Read More20191209-1215 Biocon and Equillium Expand Collaboration to Australia, NZ India headquartered Biocon Ltd and US based Equillium Inc., announced on December 13th that they have expanded collaboration and license agreement …
Read More20190902-0908 Weekly in Asia Korea’s JW Pharmaceutical Acquires Vietnamese Drugmaker Recently, the Southeast Asian drug market, such as Vietnam, is growing at a rapid pace, however, it is difficult for …
Read More20190818-0824 Weekly in Asia CStone Gets Approval for Phase I trial of CDK4/6 Inhibitor CS3002 in Australia CStone Pharmaceuticals, a leading China-based biopharmaceutical company, recently announced that it has received …
Read MoreBy Rajaneesh K. Gopinath, Ph.D. The world’s first PARP inhibitor to be approved by the USFDA for the treatment of BRCA-mutated advanced ovarian cancer, succeeded in the phase III trials …
Read MoreThe continuous development of new drugs indicates the pharmaceutical industry is still going strong. As technology continues to reinvent itself with time, various IT tech are introduced to support drug …
Read MoreBy Ajay V. Patil US FDA approved Lynparza®Olaparib for the maintenance treatment of adult patients with deleterious germline or somatic BRCA-mutated (gBRCAm or sBRCAm) advanced ovarian, fallopian tube or primary …
Read More